Allos AI

To add a bio or update company history, please click update information.

News from Allos AI

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

13 Jan 2026

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

Allos AI applies causal AI to reformulate complex generic drugs, improving delivery, tolerability and predictability while reducing development uncertainty.

Life Sciences
Oxford, United Kingdom
£4m
allos.ai
Update Information

More venture news

Healome Therapeutics
7 Jul 2026
Healome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences
Revolver Therapeutics
6 Jul 2026
Revolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
EquityLife Sciences
RQ Bio
25 Jun 2026
RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
Series ALife Sciences

Allos AI

News from Allos AI

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

More venture news

Healome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease

Revolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins

RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza